AUTHOR=Wang Hsiao-Chi , Xia Roger , Chang Wen-Hsin , Hsu Ssu-Wei , Wu Chun-Te , Chen Ching-Hsien , Shih Tsung-Chieh TITLE=Improving cancer immunotherapy in prostate cancer by modulating T cell function through targeting the galectin-1 JOURNAL=Frontiers in Immunology VOLUME=15 YEAR=2024 URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1372956 DOI=10.3389/fimmu.2024.1372956 ISSN=1664-3224 ABSTRACT=
Our study aimed to elucidate the role of Galectin-1 (Gal-1) role in the immunosuppressive tumor microenvironment (TME) of prostate cancer (PCa). Our previous findings demonstrated a correlation between elevated Gal-1 expression and advanced PCa stages. In this study, we also observed that Gal-1 is expressed around the tumor stroma and its expression level is associated with PCa progression. We identified that Gal-1 could be secreted by PCa cells, and secreted Gal-1 has the potential to induce T cell apoptosis. Gal-1 knockdown or inhibition of Gal-1 function by LLS30 suppresses T cell apoptosis resulting in increased intratumoral T cell infiltration. Importantly, LLS30 treatment significantly improved the antitumor efficacy of anti-PD-1